We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: Gilteritinib
MedXY News
EnglishTag

Gilteritinib

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationcritical carebiomarkersclinical trialsartificial intelligenceHypertensionCardiologyoncologytype 1 diabetespublic healthMortalitydiabetesAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Dynamic Genetic and Nongenetic RAS-Pathway Activation Drives Resistance to FLT3 and BCL2 Inhibitor Therapy in AML
Clinical Updatesdrug resistanceBCL2 inhibitor

Dynamic Genetic and Nongenetic RAS-Pathway Activation Drives Resistance to FLT3 and BCL2 Inhibitor Therapy in AML

By MedXY|Sep 24, 2026

This review synthesizes cutting-edge findings on how genetic and nongenetic RAS-pathway activation mediates resistance to combined FLT3 and BCL2 inhibition in acute myeloid leukemia, highlighting implications for treatment strategies and bi

Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations
Hematology-OncologyGilteritinib
venetoclax

Venetoclax plus gilteritinib shows potent preclinical activity in FLT3‑mutant BCL11B‑a lineage‑ambiguous leukemia: translational opportunities and trial design considerations

By MedXY|Nov 15, 2025

Preclinical work shows that combining the BCL‑2 inhibitor venetoclax with the FLT3 inhibitor gilteritinib produces deep, reproducible anti‑leukemia activity in FLT3‑mutant, BCL11B‑activated lineage‑ambiguous leukemias. BH3 profiling and sin

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease
Hematology-Oncologyacute myeloid leukemiaFLT3-ITD

Tailoring Transplant Conditioning and Maintenance Therapy in FLT3-ITD AML: Insights on NPM1 Mutations and Measurable Residual Disease

By MedXY|Nov 4, 2025

Posttransplant gilteritinib greatly benefits FLT3-ITD AML patients with NPM1 comutations, while myeloablative conditioning offers limited advantages over reduced-intensity conditioning in eradicating measurable residual disease.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
General Surgery
Optimizing Postoperative Opioid Prescriptions After Intra-Abdominal Cancer Surgery: Comparing the 5x-Multiplier and 3-Tier Models
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure